Searching the GLP-1 shortage 2026 status? Here is the short version: there is no shortage. The FDA declared the tirzepatide shortage resolved on December 19, 2024 and the semaglutide shortage resolved on February 21, 2025. Both drugs have stayed off the shortage list ever since.
That was supposed to kill the compounded copycat market. It did not. In July 2026, compounded semaglutide still sells online for $89 to $299 a month, per provider pricing pages and third-party pricing reports. This guide lays out the verified timeline, the legal fine print, and why the knockoffs refuse to die.
GLP-1 Shortage 2026: The Official Status
Neither semaglutide nor tirzepatide appears on the FDA drug shortage list in 2026. The agency ruled that Eli Lilly could meet demand for tirzepatide in December 2024, and that Novo Nordisk could meet demand for semaglutide in February 2025.
In plain terms: Wegovy, Ozempic, Zepbound, and Mounjaro are available. The bottleneck moved from the factory to the wallet. Ozempic still runs roughly $900 to $1,100 a month cash at the pharmacy counter, per telehealth pricing pages reviewed in July 2026, while brand cash-pay programs through manufacturer-linked channels start closer to $149 to $499 a month.
Why People Still Search GLP-1 Shortage 2026
Two reasons. First, a wave of patients started on cheap compounded versions during the shortage years and want to know if their supply is safe. Second, compounded sellers still advertise like the shortage never ended — some at $89 a month, a price brand manufacturers do not touch.
The shortage was the legal foundation for that entire market. The foundation is gone. The market is still standing, and the rest of this guide explains the gap.
The Full Timeline: From Shortage to Crackdown
Here is the verified sequence, from the first shortage listing to the July 2026 state of play.
| Date | What happened |
|---|---|
| March 2022 | Wegovy (semaglutide) enters the FDA drug shortage list |
| December 15, 2022 | Tirzepatide (Mounjaro) joins the shortage list |
| October 2, 2024 | FDA first removes tirzepatide from the list; a compounding trade group sues |
| December 19, 2024 | FDA issues a declaratory order: tirzepatide shortage resolved |
| February 18 / March 19, 2025 | Compounding grace periods end for tirzepatide (503A pharmacies, then 503B facilities) |
| February 21, 2025 | FDA declares the semaglutide shortage resolved |
| April 22 / May 22, 2025 | Compounding grace periods end for semaglutide (503A, then 503B) |
| September 9-16, 2025 | FDA posts a wave of warning letters to compounded GLP-1 sellers — more than 55, per trade press reports |
| February 20, 2026 | FDA warning letter to telehealth seller MEDVi over misleading compounded GLP-1 claims |
| April 30, 2026 | FDA proposes excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list; comments due June 29, 2026 |
| June 15, 2026 | FDA updates its adverse-event tally: 990 reports for compounded semaglutide, 730+ for compounded tirzepatide |
| July 2026 | Compounded GLP-1s still marketed online at $89 to $299 a month |
Note the pattern. Regulators moved in months. The market adapted in weeks.
Why a Shortage Ever Allowed Copying
Federal law normally bans compounding pharmacies from making what the FDA calls essentially a copy of an approved drug. There is one big exception. When a drug sits on the FDA shortage list, compounders may legally produce versions of it to fill the gap.
That exception built an entire discount industry between 2022 and 2025 — at roughly 70% to 90% below brand list prices, based on the $89-$299 advertised range against $1,000-plus list prices. Two types of compounders did the work. 503A pharmacies fill patient-specific prescriptions, while 503B outsourcing facilities mass-produce under federal manufacturing rules, per the FDA’s compounding Q&A.
When the shortages ended, so did the exception — after short grace periods that all expired by May 22, 2025. Since then, selling copies of semaglutide or tirzepatide has had no shortage-based legal cover. Whether today’s workarounds hold up is the subject of our guide to whether compounded GLP-1s are legal.
One thing was never in question: compounded GLP-1s are not FDA-approved. The FDA states it does not review them for safety, effectiveness, or quality. That was true during the shortage at $199 a month, and it is true now at $89.
Why Compounded Versions Persist in 2026
Four forces keep the copycat market alive a full year after its legal basis expired.
1. The price gap is enormous. Compounded semaglutide advertises at $89 to $299 a month; brand list prices exceed $1,000. Even discounted brand cash-pay programs leave a gap of $100 or more per month. Our semaglutide cost and tirzepatide cost breakdowns show the spread in dollars.
2. The personalized-dose argument. Sellers now market custom strengths, added vitamins like B12, or slower titration schedules. The claim: a tweaked formula is no longer essentially a copy, so 503A patient-specific compounding rules still allow it. The FDA has pushed back hard, warning that it received adverse event reports — some requiring hospitalization — tied to dosing errors and to doses beyond the approved labels.
3. The 503B door is not fully shut — yet. On April 30, 2026, the FDA proposed excluding all three GLP-1s from the 503B bulks list after finding no clinical need for outsourcing facilities to compound them. Comments were due June 29, 2026, and no final decision had been announced as of mid-July. Until it is final, some players treat the gray zone as a business model.
4. Enforcement moves one letter at a time. A warning letter names one seller. It does not shut down the other hundred, and new storefronts launch monthly. Case in point: one operator received an FDA warning letter dated June 8, 2026 over its altRx brand’s GLP-1 marketing, per the letter posted on FDA’s site — while the brand’s site still advertised compounded semaglutide at $89 a month in July 2026.
The FDA Crackdown, By the Numbers
The agency is not idle. The numbers tell the story better than any press release.
990 and 730. As of May 31, 2026, the FDA had received 990 adverse event reports for compounded semaglutide and more than 730 for compounded tirzepatide. The agency adds that most compounding pharmacies are not required to report at all, so the real count is likely higher.
55-plus warning letters. The September 2025 wave hit household names, including a September 9, 2025 letter to Hims & Hers Health for false or misleading compounded semaglutide marketing under the Hers brand, per the FDA letter and company coverage. Letters kept coming in 2026: MEDVi’s February 20, 2026 letter called out claims like same active ingredient as Wegovy and Ozempic, plus labels implying MEDVi compounded drugs it did not make.
Zero lawful salt forms. The FDA says semaglutide sodium and semaglutide acetate — salt forms some compounders use — are different active ingredients with no lawful basis for compounding.
One import alert. Import alert 66-80 now screens foreign GLP-1 raw ingredients with potential quality problems at the border. The FDA has also warned sellers pushing retatrutide, a still-unapproved molecule that cannot legally be compounded at all.
The market is reacting. Hers limited compounded semaglutide to documented medical necessity as of March 2026, per Healthline reporting, and Ro’s July 2026 pricing page lists only FDA-approved brand-name GLP-1s.
If You Are Taking a Compounded GLP-1 Right Now
No panic — but no autopilot either. Three moves protect you.
Ask who makes your medication. Get the pharmacy’s name and state license, and ask whether it is a 503A pharmacy or 503B facility. The FDA flags labels naming pharmacies that do not exist as a known fraud pattern, and says products arriving warm or without cold packs should not be used.
Get the clinical need in writing. If your dose is customized, your prescriber should document why an FDA-approved product cannot meet your need. No documentation, no defensible prescription.
Have a plan B before supply breaks. If the FDA finalizes its 503B exclusion, compounded supply could contract within weeks, not months. Our guide to switching GLP-1 medications covers how prescribers move patients between products without losing progress.
Remember what the headline trial numbers actually tested. The 14.9% average weight loss at 68 weeks came from FDA-approved semaglutide 2.4 mg in the STEP 1 trial, and the up to 20.9% at 72 weeks came from approved tirzepatide in SURMOUNT-1, both published in the New England Journal of Medicine. Compounded copies were in neither trial. And per the NIDDK, every prescription option works alongside diet and activity changes — not instead of them.
The Bottom Line on the GLP-1 Shortage in 2026
The shortage is history: tirzepatide resolved December 19, 2024, semaglutide February 21, 2025. The legal permission to mass-copy these drugs died with it by May 2025.
What persists is a price war. Brand-name GLP-1s are available but cost real money, and compounded sellers keep filling the gap at $89 to $299 a month — unapproved, uneven, and under growing FDA fire. The 503B bulks decision could end the era for good. Until then, know exactly which version you are injecting, and what fine print came with the discount.